Melanoma immunotherapy study at Strasbourg Hospital
Part of Cancer, Skin clinical trials.
This study looks back at medical records to find out what factors helped people with advanced melanoma respond completely to immunotherapy. It includes patients treated at a specific hospital in France between 2013 and 2021.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced melanoma that cannot be removed by surgery or has spread (stage III or IV).
- You were treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4 drugs) as a main treatment.
- You received your treatment and follow-up at the Dermatology Department of Strasbourg University Hospitals in France.
- You started immunotherapy between January 2013 and December 2021.
- You have been followed for at least 3 months after starting immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This study looks at how people with advanced melanoma (a serious skin cancer) feel during treatment with immunotherapy. It aims to better understand the symptoms they experience, so doctors can help manage them.
Hear when a new Stage III Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.